Melissa A Geller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9379627/publications.pdf

Version: 2024-02-01

55 papers

3,320 citations

218381 26 h-index 50 g-index

56 all docs

56
docs citations

56 times ranked 6181 citing authors

#	Article	IF	CITATIONS
1	Gene expression markers of Tumor Infiltrating Leukocytes. , 2017, 5, 18.		572
2	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy, 2011, 13, 98-107.	0.3	374
3	Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nature Communications, 2019, 10, 567.	5.8	193
4	Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer. Stem Cells, 2016, 34, 93-101.	1.4	181
5	Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight, 2018, 3, .	2.3	165
6	Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 2011, 3, 1445-1459.	1.0	134
7	Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells. Oncotarget, 2016, 7, 43150-43161.	0.8	108
8	Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. Journal of Ovarian Research, 2010, 3, 21.	1.3	94
9	Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. Gynecologic Oncology, 2015, 138, 609-613.	0.6	91
10	A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecologic Oncology, 2013, 128, 65-70.	0.6	89
11	Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecologic Oncology, 2017, 144, 598-606.	0.6	82
12	Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. Gynecologic Oncology, 2019, 153, 149-157.	0.6	79
13	Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer. Journal of Cancer, 2012, 3, 217-225.	1.2	78
14	A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich―method for stage III, IV, and recurrent endometrial cancer. Gynecologic Oncology, 2011, 121, 112-117.	0.6	64
15	Cervical cytology and multiple type HPV infection: A study of 8182 women ages 31–65. Gynecologic Oncology, 2014, 133, 405-408.	0.6	64
16	Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunology, Immunotherapy, 2010, 59, 1877-1884.	2.0	61
17	Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy, 2013, 15, 1297-1306.	0.3	54
18	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 2020, 12, 2659.	1.7	54

#	Article	IF	CITATIONS
19	Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecologic Oncology, 2004, 95, 632-636.	0.6	47
20	A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich―method for high risk endometrial carcinoma. Gynecologic Oncology, 2010, 118, 19-23.	0.6	43
21	Development and pilot of an advance care planning website for women with ovarian cancer: A randomized controlled trial. Gynecologic Oncology, 2013, 131, 430-436.	0.6	43
22	Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 918-925.	1.2	42
23	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2138-2147.	0.8	40
24	Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. Cancer Immunology Research, 2020, 8, 1139-1149.	1.6	39
25	Genetic Risk Assessment for Women with Epithelial Ovarian Cancer: Referral Patterns and Outcomes in a University Gynecologic Oncology Clinic. Journal of Genetic Counseling, 2013, 22, 662-673.	0.9	34
26	Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. Gynecologic Oncology, 2014, 133, 78-82.	0.6	32
27	The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecologic Oncology, 2017, 144, 159-166.	0.6	30
28	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Science Translational Medicine, 2022, 14, eabg8402.	5.8	28
29	A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. Bone, 2015, 73, 90-97.	1.4	27
30	Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. Gynecologic Oncology, 2014, 135, 318-324.	0.6	26
31	A multi-institutional study of outcomes in stage l–III uterine carcinosarcoma. Gynecologic Oncology, 2015, 139, 275-282.	0.6	25
32	Improving Referral for Genetic Risk Assessment in Ovarian Cancer Using an Electronic Medical Record System. International Journal of Gynecological Cancer, 2014, 24, 1003-1009.	1.2	24
33	Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women. Surgery for Obesity and Related Diseases, 2014, 10, 921-926.	1.0	24
34	<p>Ultrasound-guided subcostal transversus abdominis plane block with liposomal bupivacaine compared to bupivacaine infiltration for patients undergoing robotic-assisted and laparoscopic hysterectomy: a prospective randomized study</p> . Journal of Pain Research, 2019, Volume 12, 2087-2094.	0.8	21
35	Sexual quality of life after the treatment of gynecologic cancer: what women want. Supportive Care in Cancer, 2019, 27, 4649-4654.	1.0	21
36	Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. JAMA Oncology, 2019, 5, 1222.	3.4	19

#	Article	IF	CITATIONS
37	A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer. Hereditary Cancer in Clinical Practice, 2018, 16, 13.	0.6	18
38	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2018, 151, 18-23.	0.6	18
39	A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial. Gynecologic Oncology, 2019, 153, 100-107.	0.6	17
40	A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics. Clinical Proteomics, 2014, 11, 30.	1.1	16
41	Effects of web-based instruction and patient preferences on patient-reported outcomes and learning for women with advanced ovarian cancer: A randomized controlled trial. Journal of Psychosocial Oncology, 2018, 36, 503-519.	0.6	16
42	Sonosensitizerâ€Functionalized Graphene Nanoribbons for Adhesion Blocking and Sonodynamic Ablation of Ovarian Cancer Spheroids. Advanced Healthcare Materials, 2021, 10, 2001368.	3.9	16
43	Learning about ovarian cancer at the time of diagnosis: Video versus usual care. Gynecologic Oncology, 2010, 119, 370-375.	0.6	15
44	A model for patient-direct screening and referral for familial cancer risk. Familial Cancer, 2016, 15, 707-716.	0.9	14
45	The Use of Sodium Hyaluronate–Carboxymethylcellulose (HA-CMC) Barrier in Gynecologic Malignancies: A Retrospective Review of Outcomes. Annals of Surgical Oncology, 2009, 16, 499-505.	0.7	13
46	Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. Translational Oncology, 2022, 16, 101318.	1.7	12
47	Propensity-Weighted Comparison of Long-Term Risk of Urinary Adverse Events in Elderly Women Treated For Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 586-593.	0.4	11
48	Designing an Educational Website to Improve Quality of Supportive Oncology Care for Women with Ovarian Cancer: An Expert Usability Review and Analysis. International Journal of Human-Computer Interaction, 2016, 32, 297-307.	3.3	11
49	Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution. Journal of Lower Genital Tract Disease, 2018, 22, 184-188.	0.9	9
50	Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 143, 93-97.	0.5	7
51	Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich―method for stage III, IV, and recurrent endometrial cancer. Gynecologic Oncology Research and Practice, 2016, 3, 6.	3.6	6
52	Effect of an Electronic Health Record Decision Support Alert to Decrease Excess Cervical Cancer Screening. Journal of Lower Genital Tract Disease, 2019, 23, 253-258.	0.9	5
53	Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy. Biotechnology and Bioengineering, 2020, 117, 3066-3080.	1.7	5
54	Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer. Gynecologic Oncology, 2021, 160, 193-198.	0.6	4

#	Article	IF	CITATIONS
55	Differences in Family Planning and Fertility Among Female and Male Gynecologic Oncologists. Women S Health Reports, 2021, 2, 78-84.	0.4	3